Vir Biotechnology Inc. (VIR)
| Bid | 6.05 |
| Market Cap | 842.88M |
| Revenue (ttm) | 73.11M |
| Net Income (ttm) | -521.96M |
| EPS (ttm) | -3.83 |
| PE Ratio (ttm) | -1.59 |
| Forward PE | -1.99 |
| Analyst | Buy |
| Ask | 6.45 |
| Volume | 687,243 |
| Avg. Volume (20D) | 1,228,790 |
| Open | 6.12 |
| Previous Close | 6.12 |
| Day's Range | 5.95 - 6.21 |
| 52-Week Range | 4.95 - 14.45 |
| Beta | 1.14 |
About VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus....
Analyst Forecast
According to 7 analyst ratings, the average rating for VIR stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 227.60% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · businesswire.com
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care ConferenceSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Hea...